PB0093 - Thromboembolism and its Management in Hospitalized COVID-19 Patients Using Modified Caprini Risk Score: A Single Center Experience in Ethiopia

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Tamrat Assefa Tadesse, Master of Science in Pharmacy practice

Assistant Professor and Clinical Pharmacy Specialist
Addis Ababa University
Addis Ababa, Adis Abeba, Ethiopia

Co-Author(s)

AT

Ashenafi Teklu

Pharmacist
School of Pharmacy, College of Health Sciences, Addis Ababa University
Addis Ababa, Adis Abeba, Ethiopia
AA

Alfoalem A. Abiye

Assistant Lecturer of Pharmacology
School of Pharmacy, College of Health Sciences, Addis Ababa University
Addis Ababa, Adis Abeba, Ethiopia

Background: Reports indicated association of COVID-19 with coagulation dysfunction and venous thromboembolism (VTE) prevalence was in the range of 20–40%. All patients with COVID-19 who are hospitalized should receive pharmacologic prophylaxis unless they have contraindications.

Aims: To assess VTE risk, incidence and its management in patients with COVID-19 admitted to Tikur Anbessa Specialized Hospital (TASH).

Methods: A retrospective study was conducted among 146 COVID-19 patients admitted to TASH. A pre-tested data abstraction format was used to collect patients’ clinical information and VTE risk by using the modified Caprini Risk Score in COVID-19. We used Statistical Package for the Social Sciences (SPSS) version 26 for data analysis. Descriptive statistics was used to summarize the findings and binary logistic regression analysis to assess association between the variables of interest.

Results: Result: Out of 146 patients, 57.53% were males and mean age was 45.56 ± 18.17 years. All patients were at risk of developing VTE. The most often observed VTE risk factors were being COVID-19 symptomatic (88.40 %), serious lung diseases (56.2%) and age > 40 years (52.10 %). The incidence of VTE was 23 (15.75 %) and majorly (91.3%) occurred in highest VTE risk (≥ 5 score) patients, >40 years patients and in patients with severe COVID-19 symptoms (100%). However, parenteral thromboprophylaxis was prescribed only for 98 (67.12 %) patients. Out of 23 patients developed VTE, 15 didn’t receive prophylaxis and the remaining 8 received the thromboprophylaxis. Unfractionated heparin (UFH) was the most widely used prophylaxis. For patients who developed VTE, majority of them 20 (86.96%) were given therapeutic dose of UFH.

Conclusion(s): All patients with COVID-19 were at risk of developing VTE. Only one third received thromboprophylaxis. The incidence of VTE was high and majorly occurred in patients that didn’t receive prophylaxis.